Evonik Won't Talk About BASF — So It Talked About Capital Instead
A takeover approach it declines to discuss, a methionine peak that is passing, and a new obsession with the denominator of return on capital.
EVK.DE · Earnings Call · 2026-11-03
The Bid in the Room That Nobody Will Discuss
Evonik's Q3 call opened with an unusual piece of housekeeping: a new head office in Essen, an interim CEO in Claus Rettig while Christian Kullmann recovers from surgery, and a live takeover approach from BASF that management has decided not to engage with. Rettig was explicit that the topic would not be revisited — not in prepared remarks, and not once across the entire Q&A, even when Martin Roediger of Kepler Cheuvreux asked directly what the real reason for the silence was.
As you know, we have decided not to enter into negotiations with BASF on the basis on the information we have received so far... We remain fully focused on our strategic direction and our development as an independent company.
That is the tension running through this whole call. The single most important fact for shareholders — a larger peer has made an approach — is the one item management has walled off. Everything else on the call is, in effect, the counter-argument: here is why Evonik is worth more alone. The company has promised an "informational and confidential exchange" with BASF, which is a polite way of saying it will listen without negotiating.
So the burden falls on the operating story to carry the independence case. And to management's credit, this quarter it largely does.
From Fixed Costs to the Denominator
The most interesting thing in the keyword set is what has fallen away. For several quarters, Evonik Tailor Made and fixed costs were the headline. In Q1 2026 the single highest-ranked company keyword was fixed cost savings; in Q2 it was Tailor Made itself, with a skeptical analyst hammering on whether the net savings were ever visible in the P&L. Michael Rauch effectively conceded the point in August: “the net impact basically on the savings is not as pronounced as it was anticipated.” — Michael Rauch, Chief Financial Officer (CFO) · 2026-08-04
This quarter the framing has been rebuilt from the bottom up. The top-ranked keyword is now capital employed, with return on capital and cost of capital close behind — a shift from "we are cutting costs" to "we are shrinking the capital base we earn on." Rettig's opening argument was almost a manifesto: only one in five chemical companies currently earns its cost of capital, and Evonik intends to be in that fifth by 2029 with a ROCE around 11%.
The mechanics are concrete rather than rhetorical. CapEx is guided to a run rate of roughly €700 million in the coming years, below depreciation — “This is a reflection of the reshaping of our portfolio, less capital-intensive businesses with higher returns, like additives or biotech solutions.” — Michael Rauch, Executive Board Member / CFO · 2026-11-03 Working capital is targeted down from about 18% of sales to 17%, and more importantly rebalanced across the year rather than crammed into a December squeeze. ROCE guidance for 2026 was raised to more than 8%.
The one number that gives this credibility is leverage. Net financial debt is down almost €400 million year-on-year, gearing sits at 2.1x, Moody's moved the rating to Baa1 in late August, and free cash flow conversion of 40% implies roughly €850 million of cash generation this year. That is a balance sheet being groomed for optionality — and Rettig was happy to spell out what the optionality is for: growth fields in additives, cosmetic ingredients and biotech, with Custom Solutions as the hunting ground.
Methionine: The Shakeout Now Has Names and Tonnages
Nothing follows this company like methionine. On the August call, Chetan Udeshi of JPMorgan put the criticism bluntly: “there's the impression that everybody has that the Evonik numbers this year have basically just benefited from methionine prices. It's like one trick pony.” — Chetan Udeshi, Analyst · 2026-08-04 Kullmann had answered with a thesis rather than a dataset — that 2027 would bring a “shakeout” — Christian Kullmann, Chief Executive Officer (CEO) · 2026-08-04 of weaker producers.
This quarter the thesis got its evidence. Rettig walked through the supply map with unusual specificity: CJ permanently closing its Malaysian plant from mid-October, with only about 100kt of its 170-180kt nameplate actually running; Sumitomo offline until year-end; Leben Crop Science's 100kt Inner Mongolia plant likely not onstream until Q2 2027 because "it's already pretty cold in Inner Mongolia"; Adisseo adding 140kt at the end of this year. The Inner Mongolia detail is a genuinely new level of granularity, as is the framing around existing players behaving more predictably than new entrants.
Against that, prices are already past the peak: “we are at a peak prices in June, July. Since then, we see a normalization trend and strong volumes.” — Claus Rettig, Member of the Executive Board · 2026-11-03 Management insists this is not a cliff — the entry point into 2027 is higher than a year ago, Q4 is heavily booked, and order books support the claim of a good start to next year. That Order books keyword now ranks third for the company, a striking change from a year ago when visibility was described as "super low."
Skeptics should note the asymmetry: Methionine prices is a keyword that never leaves this company's top-30, and the equity has effectively been a methionine proxy for four quarters. Nothing on this call breaks that link — it only argues the link is less fragile than feared.
The Hole Is Custom Solutions
The genuine soft spot is the segment management wants to build around. Advanced Technologies carried the quarter — methionine pricing plus Polyamide 12 share gains and firm crosslinkers — while Custom Solutions managed only about 7% EBITDA growth. Rettig did not hide it: “only a sales growth of 7% or EBITDA growth of 7% is, of course, much less than the other one.” — Claus Rettig, Member of the Executive Board · 2026-11-03 The culprit is base cosmetic ingredients shrinking, offsetting strength in delivery systems and active ingredients.
This is the same argument analysts have been making for two quarters — that the quarter is an Advanced Technologies story dressed as a group story — and it remains unresolved. The fix is portfolio surgery: Oxeno to be signed in the coming months, after which Evonik holds only a third of the chemical activity at Marl, and SYNEQT to follow.
Two external tailwinds are worth monitoring. First, the EU's Critical Chemical Alliance has put 49 molecules on a preliminary list, eight of them Evonik's, including methionine and isophorone diamine — a potential Critical Chemical Alliance support mechanism for exactly the asset that frightens investors most. Second, the broader consolidation wave in European chemicals, where the Olin Huntsman combination sits alongside the BASF interest, is precisely the environment in which a well-deleveraged, ROCE-focused Evonik becomes either a consolidator or a target. Management says it wants to be the former. The market will decide whether the BASF silence is a negotiating tactic or a strategy.
For now, the call's real message is narrower and better: the cost-cutting story has been retired in favour of a capital-efficiency story, the methionine peak is being managed rather than denied, and the balance sheet is being cleaned up on purpose. Whether that is enough to justify independence is the question nobody on this call was allowed to ask.